A. Sommer

发表

Detection Rates of Ductal Carcinoma in Situ with Biennial Digital Mammography Screening: Radiologic Findings Support Pathologic Model of Tumor Progression.

H. Hense, W. Heindel, J. Wellmann, 2017, Radiology.

[Physical and technical quality assurance in German breast cancer screening: progress report of the Reference Center Muenster after three years].

W. Heindel, H. Lenzen, R. Girnus, 2009, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

Digital mammography screening with photon-counting technique: can a high diagnostic performance be realized at low mean glandular dose?

W. Heindel, H. Lenzen, R. Girnus, 2014, Radiology.

Relationship between detector size and the need for extra images and their effect on radiation exposure in digital mammography screening.

W. Heindel, H. Lenzen, A. Sommer, 2014, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

Digital breast tomosynthesis plus synthesised images versus standard full-field digital mammography in population-based screening (TOSYMA): protocol of a randomised controlled trial

H. Hense, W. Heindel, J. Gerss, 2018, BMJ Open.

Guideline for determining the mean glandular dose according to DIN 6868-162 and threshold contrast visibility according to the quality assurance guideline for digital mammography systems.

A. Sommer, S. Schopphoven, I. Land, 2014, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[Guideline for the additional test positions according to the EPQC 4th Edition for Digital Mammography Systems].

H. Lenzen, A. Sommer, S. Schopphoven, 2009, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

Evaluation of the New DIN Standard for Quality Assurance of Diagnostic Displays - Technical Review DIN 6868-157.

H. Lenzen, A. Sommer, K. Entz, 2018, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial.

H. Hense, W. Heindel, J. Gerss, 2022, The Lancet. Oncology.